Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The acquisition of SPR Therapeutics will allow Medtronic to expand its portfolio of neuromodulator medical devices. The deal is expected to close in 2027.
These third-party marketers earn commissions from their insurer clients not only upon initial signups but also every time “their” enrollees renew without changing plans.
The agency cited free speech as its reasoning for rescinding the long-standing policy. While in place, the rule barred companies that agreed to settlements with the Securities and Exchange Commission from publicly denying allegations made by regulators.
RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model.
The company made the changes after its manufacturer rebates for insulin were challenged by the Federal Trade Commission. Among other shifts, Optum said 100% of all rebates will be distributed to customers by 2028.
Healthcare research outfit KLAS is out with its 2023 Best in KLAS awards recognizing excellence in healthcare software and services, and the Sweden-based imaging IT and cybersecurity company Sectra tops the field of U.S. PACS vendors—again.
The American College of Radiology is cheering a Feb. 6 decision by a federal judge in Texas who ruled that parts of the independent dispute resolution (IDR) process in the Surprise Billing Final Rule violate the Administrative Procedure Act.
Radiology that facilitates the sharing of resources and touchpoints within an enterprise but across geographic locales is the future of the specialty, according to two Harvard radiology researchers.
A therapeutic oncology company has been cleared to market a cancer treatment that that turns a tumor’s own biology into a self-signaling target for radiation therapy.
Whatever specific shape work takes in the near and distant future, it’s likely the COVID-19 era will be looked back upon as a before-and-after dividing line.